Back to Search
Start Over
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome
- Publication Year :
- 2011
-
Abstract
- Summary Objective The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS). Design Clinical Trial. Patients We recruited 140 hyperinsulinaemic overweight women with PCOS in their reproductive age. Metformin treatment (500 mg × 3/die) was prescribed to each patient for twelve months. Measurements The primary outcome was to evaluate the prevalence of nonalcoholic fatty liver disease (NAFLD) and MS in hyperinsulinaemic overweight patients with PCOS. The secondary outcome was to evaluate, in the same patients, the effects of metformin therapy on endocrine, metabolic and hepatic parameters. Results At basal evaluation, NAFLD was diagnosed in 81 of 140 patients with PCOS (57·85%); MS was present only in the NAFLD group (32·09%vs 0%; P
- Subjects :
- Adult
medicine.medical_specialty
endocrine system diseases
Endocrinology, Diabetes and Metabolism
Overweight
Hepatic Complication
Young Adult
Endocrinology
Internal medicine
Hyperinsulinism
Nonalcoholic fatty liver disease
medicine
Humans
Hypoglycemic Agents
Young adult
Ultrasonography
Metabolic Syndrome
business.industry
Metabolic Syndrome X
nutritional and metabolic diseases
medicine.disease
Metformin
Settore MED/40 - GINECOLOGIA E OSTETRICIA
Basal (medicine)
Liver
Female
medicine.symptom
Metabolic syndrome
business
medicine.drug
Polycystic Ovary Syndrome
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....b4cd8da41f43db66744ac964fde4ea10